Majority of women with early-stage breast cancer undergoing imaging despite guidelines
the ONA take:
According to a new study published in the Canadian Medical Association Journal, researchers have found that the majority of women with early-stage breast cancer undergo imaging for metastatic cancer despite guidelines from three organizations that recommend against imaging for metastatic cancer in asymptomatic women with early-stage breast cancer.
For the study, researchers identified 26,547 women with stage I or II breast cancer diagnosed between 2007 and 2012 in Ontario, Canada.
Of those, 86% underwent at least one imaging test to detect whether the patient had developed metastatic cancer.
Specifically, imaging was performed in 80% and 93% of patients with stage I and stage II breast cancer, respectively.
The American Society of Clinical Oncology, the National Comprehensive Cancer Network, and Cancer Care Ontario recommend against imaging for the detection of metastatic cancer in asymptomatic women with stage I or II breast cancer due to the very low likelihood of metastases.
There is also a high risk for false-positives that can result in further unnecessary tests, costs, and worry.
The majority of women with early-stage breast cancer undergo imaging for metastatic cancer despite guidelines.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|